Exicure (XCUR) Total Non-Current Liabilities (2016 - 2026)
Exicure's (XCUR) quarterly Total Non-Current Liabilities came in at $4.9 million in Q1 2026, up 24.69% YoY from $3.9 million in Q1 2025, and up 13.27% on a QoQ basis from $4.3 million in Q4 2025.
Exicure (XCUR) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 10 years of Total Non-Current Liabilities data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 24.69% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 24.69% YoY) and the FY2025 annual result came in at $4.3 million, down 47.96% from the prior year.
- Total Non-Current Liabilities improved to $4.9 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $38.7 million in Q1 2022 to a low of $2.8 million in Q3 2025.
- A 4-year average of $14.4 million and a median of $6.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 84.13% — and 2026, when it advanced 24.69%.
- Tracing XCUR's Total Non-Current Liabilities over 4 years: stood at $8.4 million in 2022, then fell by 1.45% to $8.3 million in 2024, then slumped by 47.96% to $4.3 million in 2025, then rose by 13.27% to $4.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $4.9 million (Q1 2026), $4.3 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | 4.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.88 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | 8.28 Mn |
| Dec 31, 2022 | 8.41 Mn |
| Sep 30, 2022 | 32.65 Mn |
| Jun 30, 2022 | 35.79 Mn |
| Mar 31, 2022 | 38.66 Mn |
| Dec 31, 2021 | 52.98 Mn |
| Sep 30, 2021 | 63.26 Mn |
| Jun 30, 2021 | 37.17 Mn |
| Mar 31, 2021 | 37.25 Mn |
| Dec 31, 2020 | 38.28 Mn |
| Sep 30, 2020 | 37.20 Mn |
| Jun 30, 2020 | 14.37 Mn |
| Mar 31, 2020 | 20.42 Mn |
| Dec 31, 2019 | 34.52 Mn |
| Sep 30, 2019 | 8.71 Mn |